Fig. 7

Therapeutic treatment with IL-9 ameliorates EAE disease. (A) The graph shows representative clinical courses of EAE IL-9 and EAE VHL mice treated starting from the day of disease onset. IL-9 therapeutic treatment significantly ameliorated EAE disease progression. EAE VHL N = 8, EAE IL-9 N = 8; Mann-Whitney test from 19 to 28 dpi, *** p < 0.001). (B) MSNs from mice therapeutically treated with IL-9 (grey) showed reduced half width and decay time compared to EAE VHL (black) condition. EAE VHL n = 7, EAE IL-9 n = 18; Unpaired T-test *p < 0.05. **p < 0.01